Niagen Bioscience
Logotype for Niagen Bioscience Inc

Niagen Bioscience (NAGE) investor relations material

Niagen Bioscience A.G.P. Virtual Consumer Showcase summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Niagen Bioscience Inc
A.G.P. Virtual Consumer Showcase summary12 Nov, 2026

Business and research

  • Four business lines span consumer supplements and skincare, ingredient supply, Niagen Plus IV/injections, and pharmaceutical development.

  • Management cited 52 peer-reviewed clinical studies on NR and 30 more underway; it estimated the global NAD supplement market at $3B, versus $10M 8–10 years earlier.

  • Management positioned NR as its preferred NAD precursor and cited a Norway study finding NR 2.3x more effective than NMN at elevating NAD.

Consumer products and marketing

  • Tru Niagen is a ~$100M supplement, sold mainly through Amazon and its website, with Watsons in parts of Asia and limited U.S. retail; Nestlé and Life Extension also sell NR products.

  • Direct website sales grew more than 30% last year, while sales were flat this year amid lower-priced competitors; management expects supplement growth to resume as awareness and product range expand.

  • NanoCloud skincare launched after studies indicated topical NR penetrates skin and raises NAD in skin cells; management expects a major skincare partner to launch a widely distributed product in Q1 next year.

  • Marketing investment has increased and could remain elevated for one or two quarters; a Kelly Slater campaign is intended to build brand awareness.

Ingredient and delivery businesses

  • Ingredient customers include Nestlé, H&H, and Life Extension; a Goli NR gummy was expected to launch shortly.

  • Nicotinamide riboside malate is a lower-cost ingredient intended for broader supply to supplement brands; whether to launch it under Tru Niagen remained under review.

  • Niagen Plus offers pharmaceutical-grade NR through clinics and at-home injection kits; management described the kits as selling, while its plans for aggressive investment in the channel remained undecided.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Niagen Bioscience earnings date

Logotype for Niagen Bioscience Inc
18th Annual Southwest IDEAS Conference19 Nov, 2026
Niagen Bioscience
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Niagen Bioscience earnings date

Logotype for Niagen Bioscience Inc
18th Annual Southwest IDEAS Conference19 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

ChromaDex Corporation is a biosciences company that develops and markets ingredients and consumer products based on nicotinamide riboside and other proprietary compounds. Its product portfolio supports healthy aging and cellular health, distributed through e-commerce and retail. The company is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.